Melanoma-associated antigen A1 and A3 as new candidate of diagnostic for non-small cell lung cancer

Abstract

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

The MAGE A1-A10 Expression associated with Histopathological Findings of Malignant or Non-Malignant Cells in Peripheral Lung Tumors

“…Lung cancer is one of cancer that is usually diagnosed at an advanced stage. One of the obstacles encountered in diagnosing lung malignancy is the location of the deep tumor in the thoracic cavity (Marhana et al, 2021;Marhana et al, 2022). Therefore, specimens were collected in the process of diagnosing lung malignancy with interventions, such as core biopsy, fine needle aspiration biopsy, forceps biopsy, bronchoalveolar lavage, and brushing (Marhana et al, 2021).…”

“…One of the obstacles encountered in diagnosing lung malignancy is the location of the deep tumor in the thoracic cavity (Marhana et al, 2021;Marhana et al, 2022). Therefore, specimens were collected in the process of diagnosing lung malignancy with interventions, such as core biopsy, fine needle aspiration biopsy, forceps biopsy, bronchoalveolar lavage, and brushing (Marhana et al, 2021). Compared with the fine needle aspiration biopsy, the core biopsy procedure showed lower complications, such as pneumothorax and hemoptysis (Yao et al, 2012).…”

“…One of the possible approaches for diagnosing patients with lung tumors in the peripheral areas is to perform a biopsy. A core biopsy can be performed in the thoracic cavity under ultrasound guidance or computed tomography (Marhana et al, 2021). The specimen obtained by core biopsy is quite adequate and can be used to specify the type of histopathological diagnosis of lung cancer and also contributes to the selection of appropriate therapy for lung tumor patients (Huang et al, 2021;Zhang et al, 2022;Marhana et al, 2022).…”